OM:EQLHealthcare
Margin Compression At EQL Pharma (OM:EQL) Challenges Defensive Generics Narrative
Latest Quarter Sets the Stage for EQL Pharma’s Next Chapter
EQL Pharma (OM:EQL) just posted Q3 2026 revenue of 118.9 million SEK with basic EPS of 0.33 SEK, alongside trailing twelve month EPS of 1.00 SEK on 425.8 million SEK of revenue. These figures put fresh numbers behind the recent share price of 61.5 SEK. The company has seen quarterly revenue move from 92.2 million SEK in Q3 2025 to 118.9 million SEK in Q3 2026, while basic EPS shifted from 0.35 SEK to 0.33 SEK over the same periods...